Navigation Links
Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
Date:12/14/2009

NEW HAVEN, Conn., ,Dec. 14 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced that it had received a complete response letter from the U.S. Food and Drug Administration ("FDA") related to its New Drug Application ("NDA") for Onrigin(TM) (laromustine) injection submitted in February 2009. The letter indicates that the FDA cannot approve the Company's NDA in its present form and provides recommendations to address remaining issues.

Alan Kessman, Chief Executive Officer, responded, "Based on the previously disclosed results of the Oncologic Drug Advisory Committee Meeting in September, we expected that the FDA would ask us to conduct an additional randomized study of Onrigin(TM) prior to approval. The complete response letter confirms our expectation."

The complete response letter advised that the Company complete a randomized study or studies to define the efficacy and safety of Onrigin(TM) in the patient population proposed for the indication, and that the study or studies should be designed to demonstrate a survival benefit that is clearly attributable to Onrigin(TM) with an acceptable safety profile in a well-characterized patient population. In addition to clinical and statistical recommendations, the letter also addressed clinical pharmacology and manufacturing issues. The complete response letter also requested that the Company provide an update on Onrigin(TM) safety information when the issues above had been addressed.

In connection with its previously disclosed review of strategic alternatives, the Company also announced that it had terminated its agreement with Merriman Curhan Ford & Co. and that it had retained Roth Capital Partners, LLP as its advisor to assist the Company in its evaluation of strategic alternatives. As previously announced, the Company does not have sufficient capital to fund a new randomized study of Onrigin(TM) and if the Company
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... Fla. , May 18, 2013 Although ... and are considered the most sensitive method for detecting ... effective in preventing cancer cases 3 . EndoChoice ® ... new Fuse™ system significantly improves the accuracy of this ... by colonoscopists. EndoChoice will be discussing these clinical trial ...
(Date:5/18/2013)... May 18, 2013 The Open Paradigm ... Occupy Psychiatry , and leading organizations ... announces a social media campaign showcasing video testimonials ... model, which focuses on pathology and illness rather ... the American Psychiatric Association,s (APA) rollout of its ...
(Date:5/18/2013)... 18, 2013 Faruqi & Faruqi, LLP, ... potential securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" ... http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation ... violated federal securities laws by issuing materially false ... drug trials for Tivopath (tivozanib) (titled "TIVO-1").  Specifically, ...
Breaking Medicine Technology:New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... , July 19, 2010 Today, Novo Nordisk announced the,landmark recruitment of ... effects of modern insulins in,the management of type 2 diabetes.[1] , ... Spanning 28 countries across 4 continents and involving ... therapy. , , , ...
... Focused Ultrasound Surgery Foundation has announced that eight leading manufacturers are ... Focused Ultrasound, scheduled for October 17 through 20 near ... , , ... edge preclinical, translational and clinical research related to one of today,s ...
Cached Medicine Technology:World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 2World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 3MR-Guided Focused Ultrasound Symposium Announces Sponsors 2MR-Guided Focused Ultrasound Symposium Announces Sponsors 3
(Date:5/18/2013)... FRIDAY, May 17 (HealthDay News) -- As the American ... considered the "bible" of modern psychiatry this weekend, the ... unprecedented, the amount of commentary and debate and criticism," ... Association (APA). "It,s been an interesting phenomenon, but the ... it and then make your own determination of how ...
(Date:5/18/2013)... May 18 (HealthDay News) -- Children who swallow high-powered ... remove the objects, according to a new study. ... in New Orleans, found that more than 79 percent ... either surgery or an endoscopic procedure, in which a ... tract. Only 21 percent of these cases can be ...
(Date:5/18/2013)... News) -- Just a few extra cups of coffee ... autoimmune liver disease known as primary sclerosing cholangitis (PSC), ... Clinic in Rochester, Minn., found that drinking coffee was ... which can lead to cirrhosis of the liver, liver ... prove a cause-and-effect relationship. "While rare, PSC ...
(Date:5/18/2013)... 18, 2013 MOOSGO.COM published an original art ... book features a group of artists who share their creations ... illustrations and paintings. Exclusively for iPad . , ... songs and videos that reflect the signature idiosyncrasy and passion ... the Apple iBook Store and it includes a free ...
(Date:5/18/2013)... FL (May 18, 2013) The use of ... a colonoscopy, according to new research presented today ... which begins days in advance of the procedure, ... medication to be taken at strict intervals. The ... doctors to see cancer and precancerous polyps in ...
Breaking Medicine News(10 mins):Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:New Art Book for iPad: Tango Art 2Health News:New smartphone application improves colonoscopy preparation 2
... the first time, there is reason to believe that a ... -- which triggers growth of new blood vessels in hearts ... viable new option for thousands of patients suffering with heart ... range from drugs to surgical procedures that open blocked arteries ...
... doctors has found that aspirin works just as well as ... suspected that Warfarin was more effective but that aspirin was ... are equals in both respects. ,Both drugs slow ... the final stages of the most common type of stroke ...
... retrovirus that binds to receptors found on membranes of immune ... is internalized, copied into DNA, then migrates into the nucleus ... In many cases, the inserted viral genes remain dormant, sometimes ... Acquired Immune Deficiency Syndrome is a collection of 26 clinical ...
... implants in a woman's uterus, the more likely she is ... the latest New England Journal of Medicine details the most ... of pregnancy - influences its success or failure. ,Fertilised ... anywhere from six to 12 days after ovulation, the researchers ...
... children into learning too much too soon is more ... nursery experts. This setting of targets for three to ... as tantrums and bed-wetting, rather than achieve accelerated learning, ... are often intimidated by an early start to their ...
... asthma risks,say the researchers.Traditional student digs with mouldy and ... researchers. ,A study of over 20,000 Finnish students found ... risk of asthma, but left residents with a greater ... in damp houses were found to need more antibiotics ...
Cached Medicine News:Health News:More about HIV 2Health News:More about HIV 3
... Captia™ Varicella- Zoster Virus (VZV) IgG Enzyme- ... the detection and quantitative determination of IgG ... serum specimens may be used for the ... and convalescent, may be used to demonstrate ...
... Varicella-Zoster Virus (VZV) IgG Enzyme-Linked Immunosorbent ... and quantitative determination of IgG antibody to ... specimens may be used for the determination ... convalescent, may be used to demonstrate seroconversion ...
Inquire...
... Trinity Biotech Captia™ Mumps IgG Enzyme-linked Immunosorbent ... and quantitative determination of IgG antibody to ... specimens may be used for the determination ... convalescent, may be used to demonstrate seroconversion ...
Medicine Products: